TIP方案一线治疗晚期中高危睾丸生殖细胞肿瘤的回顾性分析
DOI: 10.3971/j.issn.1000-8578.2018.17.1417
周莉,
唐碧霞,
崔传亮,
斯璐,
李思明,
毛丽丽,
王轩,
白雪,
盛锡楠,
连斌,
迟志宏,
郭军,
鄢谢桥
Keywords: A Meta-analysis,Metadherin-mediated Cell Proliferation and Paclitaxel Resistance in Nasopharyngeal Carcinoma,Clinical Efficacy of Liposomal Paclitaxel in Maintenance Treatment of Patients with Advanced Squamous Cell Lung Carcinoma,Combination of SAHA and Paclitaxel Induce Apoptosis of Human Cervical Cancer HeLa Cells,Comparison of Efficacy and Safety Between Liposome-paclitaxel plus Carboplatin and Paclitaxel plus Carboplatin on Epithelial Ovarian Cancer,Comparison of Clinical Effect Between mFOLFOX6 and FOLFIRI Regimen as Alternately First- and Second-line Therapy on Advanced Gastric Cancer Patients,Clinical Value of Pharmacokinetic Monitoring of Serum Paclitaxel Concentration in Paclitaxel-based Chemotherapy on Patients with Ovarian Cancer,Clinical Analysis of Radiotherapy Combined with Cisplatin-based Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma,Experiment of Different Administration Sequences of Apatinib and Paclitaxel on Lung Cancer,Knockdown of PKD1 Decreased Sensitivity of Human Salivary Gland Adenoid Cystic Carcinoma Cell Line ACC2 to Paclitaxel,Mechanism of Jinlong Capsule Reversing Paclitaxel Resistance of A549 Cells Investigated by System Biology Technology,Efficacy and Safety of Weekly Liposome-paclitaxel or Oxaliplatin Combined with Tegafur on Elderly Advanced Gastric Cancer,Killing Effect of Paclitaxel and Cisplatin on EGFR-wild and Mutant Lung Adenocarcinoma Cells and Related Molecular Mechanism,A Prospective Clinical Trial of Treatment Models on Malignant Ovarian Germ Cell Tumor Patients,miR-200c Enhances Sensitivity of Lung Cancer Cell A549 to Paclitaxel and Gefitinib and Related Mechanism
Abstract:
摘要 目的 回顾性分析紫杉醇、异环磷酰胺联合顺铂（TIP）方案作为一线治疗晚期中高危睾丸生殖细胞肿瘤的疗效和安全性。方法 选取晚期中高危男性睾丸生殖细胞肿瘤患者，一线给予TIP方案进行治疗，评估该方案的客观有效率、2年的无进展生存率（PFS）和总生存率（OS）。结果 共20例患者纳入本研究，平均用药周期为4.25周期，6 例患者获得完全缓解（30%），7例患者获得部分缓解（35%）， 客观有效率65%。中位随访时间25月，3例患者因肿瘤进展死亡。2年的PFS率为72.9%，OS率为89.1%。血液学毒性为最常见的不良反应 （95%），其中3~4级中性粒细胞减少的发生率为30%。结论 TIP方案一线治疗晚期中高危睾丸生殖细胞肿瘤较既往报道提高了患者的PFS率和OS率，不良反应可控，确立为一线方案仍需大样本临床研究
Full-Text
